AAP
JSPR icon

Arax Advisory Partners’s Jasper Therapeutics JSPR Stock Holding History

Arax Advisory Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241 Buy
+573
New +$429 ﹤0.01% 5083

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's JSPR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Jasper Therapeutics (JSPR) in Q2 2026: 573 shares worth $241. The stake represents ﹤0.01% of the portfolio and ranks #5083 among its holdings.

45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Arax Advisory Partners held 573 shares of Jasper Therapeutics worth $241 as of Q2 2026.
  • Jasper Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5083 holding.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.